Daiichi Sankyo Company vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Daiichi Sankyo Company, Limited (4568.JP)

Q3 202626 Jun – 17 Sep 2026

▲3▼1

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and Strong Revenue

EU Approvals for Datroway and Enhertu Datroway received EU first-line TNBC approval, while Enhertu gained EU tumor-agnostic approval, triggering a $25M AstraZeneca milestone. These expand treatment options and validate the ADC platform.
These approvals are major regulatory wins that open new markets and drive revenue potential.
Enhertu Reimbursement and Trial Success Enhertu secured NHS England reimbursement for HER2-low breast cancer after earlier rejection and showed strong first-line lung cancer data. This improves patient access and supports future growth.
Reimbursement and positive trial results directly impact sales and market confidence.
Strong Q1 Revenue and Raised Guidance Q1 revenue jumped 21% to ¥574.7B, prompting raised full-year guidance. This reflects robust business performance and management confidence.
Revenue growth and guidance raise are key financial indicators that drive investor sentiment.
Reimbursement Uncertainty and Undisclosed Economics The NHS pricing deal could still fall through, and confidential discounts obscure the exact financial benefit of expanded access. These factors temper the positive outlook.
These risks could limit the financial upside from approvals and reimbursements.

August 202631 Jul – 17 Sep 2026

▲4

Daiichi Sankyo's cancer drugs win approvals, trials and NHS access

Datroway approved in EU for first-line TNBC Datroway became the first TROP2 antibody-drug conjugate approved in the EU for first-line triple-negative breast cancer, with a 5-month overall survival benefit. This opens a new, large market and supports the drug's rapid sales growth, pushing 4568.JP up.
New approval directly expands the commercial opportunity for a key growth drug.
Full-year guidance raised on 21% revenue jump First-quarter revenue rose 21% to 574.7 billion yen, led by Enhertu and Datroway, and management raised full-year revenue and profit forecasts. Stronger U.S. sales and favorable currency rates underpin the upgrade, boosting investor confidence in 4568.JP.
Guidance raise signals stronger-than-expected business momentum and earnings power.
Enhertu shows strong first-line lung cancer data Enhertu cut the risk of progression or death by 37% versus standard care in first-line HER2-mutant lung cancer, with median progression-free survival of 14.3 months. Positive phase 3 results raise the chance of expanded approval, adding to 4568.JP's long-term growth outlook.
Late-stage trial success increases the probability of a new major indication for Enhertu.
NHS England reimburses Enhertu for HER2-low breast cancer England's NHS reversed an earlier rejection and will fund Enhertu for about 1,000 women a year with HER2-low metastatic breast cancer. As co-developer, Daiichi Sankyo shares in the expanded access, though confidential discounts mean the exact financial benefit is unclear.
Reimbursement win widens patient access and commercial reach for a core drug.

Latest31 Jul – 17 Sep 2026

▲4

Daiichi Sankyo's cancer drugs win approvals, trials and NHS access

Datroway approved in EU for first-line TNBC Datroway became the first TROP2 antibody-drug conjugate approved in the EU for first-line triple-negative breast cancer, with a 5-month overall survival benefit. This opens a new, large market and supports the drug's rapid sales growth, pushing 4568.JP up.
New approval directly expands the commercial opportunity for a key growth drug.
Full-year guidance raised on 21% revenue jump First-quarter revenue rose 21% to 574.7 billion yen, led by Enhertu and Datroway, and management raised full-year revenue and profit forecasts. Stronger U.S. sales and favorable currency rates underpin the upgrade, boosting investor confidence in 4568.JP.
Guidance raise signals stronger-than-expected business momentum and earnings power.
Enhertu shows strong first-line lung cancer data Enhertu cut the risk of progression or death by 37% versus standard care in first-line HER2-mutant lung cancer, with median progression-free survival of 14.3 months. Positive phase 3 results raise the chance of expanded approval, adding to 4568.JP's long-term growth outlook.
Late-stage trial success increases the probability of a new major indication for Enhertu.
NHS England reimburses Enhertu for HER2-low breast cancer England's NHS reversed an earlier rejection and will fund Enhertu for about 1,000 women a year with HER2-low metastatic breast cancer. As co-developer, Daiichi Sankyo shares in the expanded access, though confidential discounts mean the exact financial benefit is unclear.
Reimbursement win widens patient access and commercial reach for a core drug.

July 202626 Jun – 24 Jul 2026

▲4

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and NHS Pricing Deal

Datroway EU First-Line TNBC Recommendation Datroway, a TROP2 antibody-drug conjugate, was recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer. The trial showed a 5-month overall survival benefit and 43% reduction in disease progression risk. This opens a new market and boosts future revenue potential.
New regulatory milestone directly expands Daiichi Sankyo's oncology portfolio and revenue outlook.
Enhertu EU Tumor-Agnostic Approval and Milestone Enhertu became the first tumor-agnostic HER2-directed ADC approved in the EU, triggering a $25 million milestone payment from AstraZeneca. This broadens Enhertu's label to many cancer types, increasing its patient population and long-term sales potential.
New approval and immediate cash milestone reinforce Enhertu's blockbuster status and Daiichi Sankyo's earnings.
NHS Pricing Deal for Enhertu Nears AstraZeneca and Daiichi Sankyo are close to a pricing agreement with NHS England for Enhertu, which could make the drug available to nearly 1,000 women with breast cancer. A deal would expand access and add revenue, though it could still fall through.
New pricing agreement would unlock a major market and signal broader reimbursement momentum.
Enhertu Plus Pertuzumab EU First-Line Recommendation The EMA recommended Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, with a 44% reduction in progression risk and 40.7-month median progression-free survival. If approved, it would be the first new first-line option in over a decade.
New combination therapy recommendation expands Enhertu's use earlier in treatment, driving higher sales.

26 Jun – 24 Jul 2026

▲4

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and NHS Pricing Deal

Datroway EU First-Line TNBC Recommendation Datroway, a TROP2 antibody-drug conjugate, was recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer. The trial showed a 5-month overall survival benefit and 43% reduction in disease progression risk. This opens a new market and boosts future revenue potential.
New regulatory milestone directly expands Daiichi Sankyo's oncology portfolio and revenue outlook.
Enhertu EU Tumor-Agnostic Approval and Milestone Enhertu became the first tumor-agnostic HER2-directed ADC approved in the EU, triggering a $25 million milestone payment from AstraZeneca. This broadens Enhertu's label to many cancer types, increasing its patient population and long-term sales potential.
New approval and immediate cash milestone reinforce Enhertu's blockbuster status and Daiichi Sankyo's earnings.
NHS Pricing Deal for Enhertu Nears AstraZeneca and Daiichi Sankyo are close to a pricing agreement with NHS England for Enhertu, which could make the drug available to nearly 1,000 women with breast cancer. A deal would expand access and add revenue, though it could still fall through.
New pricing agreement would unlock a major market and signal broader reimbursement momentum.
Enhertu Plus Pertuzumab EU First-Line Recommendation The EMA recommended Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, with a 44% reduction in progression risk and 40.7-month median progression-free survival. If approved, it would be the first new first-line option in over a decade.
New combination therapy recommendation expands Enhertu's use earlier in treatment, driving higher sales.

Regeneron Pharmaceuticals Inc (REGN)

Q3 20264 Jul – 1 Oct 2026

▲1▼1

Regeneron's Q3: Pipeline Wins, Melanoma Setback, Sanofi Deal

Q2 earnings beat with 17% revenue growth Regeneron's Q2 revenue rose 17% to $4.29 billion, beating estimates, driven by strong Dupixent and high-dose Eylea sales, while Sanofi repayment improved margins.
Strong financial results directly boost investor confidence and the stock price.
Failed melanoma trial triggers lawsuits and $11B value loss A failed melanoma trial led to securities lawsuits and wiped out $11 billion in market value, highlighting pipeline execution risks and disappointing investors.
This major setback significantly impacted Regeneron's market value and reputation.
Sanofi alliance expands with $1B upfront but Dupixent profit-sharing unchanged Sanofi's expanded alliance brought $1 billion upfront and up to $7 billion in milestones, but left Dupixent profit-sharing unchanged, causing shares to drop 4%.
The deal has both positive financial aspects and negative implications for Dupixent economics.

September 202617 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Latest17 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

August 202627 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

27 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

July 20264 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

4 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

19 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.